Kintor Pharmaceutical Ltd (HKSE:09939) Share Price

Company Profile

Business description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.
Contact
No. 20 Songbei Road
Suzhou Industrial Park
Jiangsu
Suzhou215123
CHN
T: +86 51262639909
https://www.kintor.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136

Recommended

The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.

Steve Lambeth | 02 February 2026

We’ve raised our fair value estimate of Exxon stock.

Allen Good, CFA | 02 February 2026

Growth in areas critical to the firm’s future.

Matthew Dolgin, CFA | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,181.17	54.64	0.67%
DAX 40	24,797.52	258.71	1.05%
Dow JONES (US)	49,407.66	515.19	1.05%
FTSE 100	10,341.56	118.02	1.15%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,592.11	130.29	0.56%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,443.27	30.83	0.23%
S&P 500	6,976.44	37.41	0.54%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%